DE69128350D1 - Nukleinsäureliganden - Google Patents

Nukleinsäureliganden

Info

Publication number
DE69128350D1
DE69128350D1 DE69128350T DE69128350T DE69128350D1 DE 69128350 D1 DE69128350 D1 DE 69128350D1 DE 69128350 T DE69128350 T DE 69128350T DE 69128350 T DE69128350 T DE 69128350T DE 69128350 D1 DE69128350 D1 DE 69128350D1
Authority
DE
Germany
Prior art keywords
nucleic acid
acid ligands
nucleic acids
referred
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69128350T
Other languages
English (en)
Other versions
DE69128350T2 (de
Inventor
Larry Gold
Craig Tuerk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24138463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69128350(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69128350D1 publication Critical patent/DE69128350D1/de
Publication of DE69128350T2 publication Critical patent/DE69128350T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G01N2333/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96436—Granzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/966—Elastase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9726—Tissue plasminogen activator
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin
DE69128350T 1990-06-11 1991-06-10 Nukleinsäureliganden Expired - Lifetime DE69128350T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53642890A 1990-06-11 1990-06-11
PCT/US1991/004078 WO1991019813A1 (en) 1990-06-11 1991-06-10 Nucleic acid ligands

Publications (2)

Publication Number Publication Date
DE69128350D1 true DE69128350D1 (de) 1998-01-15
DE69128350T2 DE69128350T2 (de) 1998-03-26

Family

ID=24138463

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69133513T Expired - Lifetime DE69133513T2 (de) 1990-06-11 1991-06-10 Verfahren zur Verwendung von Nukleinsäureliganden
DE69128350T Expired - Lifetime DE69128350T2 (de) 1990-06-11 1991-06-10 Nukleinsäureliganden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69133513T Expired - Lifetime DE69133513T2 (de) 1990-06-11 1991-06-10 Verfahren zur Verwendung von Nukleinsäureliganden

Country Status (16)

Country Link
US (8) US5475096A (de)
EP (4) EP0533838B1 (de)
JP (4) JP2763958B2 (de)
KR (1) KR970002255B1 (de)
AT (2) ATE160821T1 (de)
AU (1) AU663053B2 (de)
CA (1) CA2084987C (de)
DE (2) DE69133513T2 (de)
DK (2) DK0533838T3 (de)
ES (2) ES2110444T3 (de)
GR (1) GR3025594T3 (de)
IE (1) IE911979A1 (de)
IL (2) IL98456A (de)
NZ (1) NZ238492A (de)
RU (1) RU2198931C2 (de)
WO (1) WO1991019813A1 (de)

Families Citing this family (981)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
US5476766A (en) * 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US5864026A (en) * 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6465189B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6716580B2 (en) * 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5795721A (en) * 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US6569620B1 (en) * 1990-06-11 2003-05-27 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US20040132067A1 (en) * 1990-06-11 2004-07-08 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5849890A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US5637682A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to the tachykinin substance P
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US6759392B1 (en) * 1990-06-11 2004-07-06 Gilead Sciences, Inc. High affinity RNA ligands of basic fibroblast growth factor
US5686592A (en) * 1990-06-11 1997-11-11 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US6261774B1 (en) * 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US6001988A (en) * 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5972599A (en) 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
AU8547691A (en) * 1990-09-21 1992-04-15 Fred Hutchinson Cancer Research Center Protein sequence-specific oligonucleotide sequences
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
CA2104698A1 (en) * 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
AU2580892A (en) * 1991-09-05 1993-04-05 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
WO1993014108A1 (en) * 1992-01-13 1993-07-22 President And Fellows Of Harvard College Selection of binding-molecules
US5783384A (en) * 1992-01-13 1998-07-21 President And Fellows Of Harvard College Selection of binding-molecules
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5756291A (en) * 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US6582902B1 (en) 1992-09-30 2003-06-24 Jack D. Keene Method for deriving epitopes
WO1994006934A1 (en) * 1992-09-11 1994-03-31 Duke University Method for deriving epitopes
CA2145761C (en) * 1992-09-29 2009-12-22 Larry M. Gold Nucleic acid ligands and methods for producing the same
EP0672188B1 (de) * 1992-10-14 2003-12-10 NeXstar Pharmaceuticals, Inc. Methode zur selektion von nukleinsäuren auf der basis ihrer struktur
CA2169536A1 (en) * 1993-09-08 1995-03-16 Larry Gold Nucleic acid ligands and improved methods for producing the same
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
JP3966478B2 (ja) * 1993-09-17 2007-08-29 ソマロジック、インコーポレイテッド 指数関数的富化によるリガンドの系統的進化：核酸リガンドの光選択と溶液ｓｅｌｅｘ
US6458539B1 (en) * 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
AU692212B2 (en) * 1993-12-17 1998-06-04 Roger S. Cubicciotti Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices
GB9401833D0 (en) * 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
US7153948B2 (en) 1994-04-25 2006-12-26 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US20020077306A1 (en) * 1994-07-14 2002-06-20 Ludger Dinkelborg Conjugates made of metal complexes and oligonucleotides, agents containing the conjugates, their use in radiodiagnosis as well as process for their production
IL114237A (en) * 1994-07-14 2000-08-31 Schering Ag Oligonucleotide conjugates and diagnostic processes utilizing the same
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
US5663064A (en) * 1995-01-13 1997-09-02 University Of Vermont Ribozymes with RNA protein binding site
WO1996027604A1 (en) * 1995-03-06 1996-09-12 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
WO1996034875A1 (en) * 1995-05-03 1996-11-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
CA2219106C (en) 1995-05-03 2008-09-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
AU728176B2 (en) * 1995-05-04 2001-01-04 Gilead Sciences, Inc. Nucleic acid ligand complexes
JP5637528B2 (ja) * 1995-05-04 2014-12-10 ギリード・サイエンシズ・インコーポレーテッド 核酸リガンド複合体
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US20090118481A1 (en) * 1995-06-07 2009-05-07 Gilead Sciences, Inc. High Affinity Nucleic Acid Ligands To Lectins
AU726844B2 (en) 1995-06-07 2000-11-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands that bind to and inhibit DNA polymerases
US6183967B1 (en) 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6229002B1 (en) * 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US20040220128A1 (en) * 1995-10-26 2004-11-04 Sirna Therapeutics, Inc. Nucleic acid based modulation of female reproductive diseases and conditions
US20040142895A1 (en) * 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US20040102389A1 (en) * 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
DE19543750C2 (de) * 1995-11-24 1997-10-23 Crinos Industria Farmaco Cathepsin G inhibierende Aptamere
US20020106647A1 (en) * 1996-07-24 2002-08-08 Segal Andrew H. Nucleic acid compositions and methods of introducing nucleic acids into cells
US20020022227A1 (en) * 1996-10-17 2002-02-21 Short Jay M. Morphatides: novel shape and structure libraries
US6838238B1 (en) 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
EP0968223B1 (de) 1997-01-08 2016-12-21 Sigma-Aldrich Co. LLC Biokonjugation von makromolekülen
AU5927598A (en) * 1997-01-23 1998-08-18 Immusol Incorporated Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
US5834199A (en) * 1997-04-29 1998-11-10 North Carolina State University Methods of identifying transition metal complexes that selectively cleave regulatory elements of mRNA and uses thereof
CA2220785A1 (en) * 1997-12-02 1999-06-02 Noureddine Rouissi Selective technique for rapid identification of proteins and genes and uses thereof
US20070166741A1 (en) * 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6261783B1 (en) 1997-12-15 2001-07-17 Gilead Sciences, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US5989823A (en) 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6268131B1 (en) 1997-12-15 2001-07-31 Sequenom, Inc. Mass spectrometric methods for sequencing nucleic acids
WO1999033971A1 (en) * 1997-12-31 1999-07-08 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
DE19800899A1 (de) * 1998-01-13 1999-07-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Oligoliganden mit Bindungsvermögen etc.
US6537747B1 (en) 1998-02-03 2003-03-25 Lucent Technologies Inc. Data transmission using DNA oligomers
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6180348B1 (en) 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6225063B1 (en) 1998-05-22 2001-05-01 University Technology Corporation RNA channels in biological membranes
EP1112377A4 (de) * 1998-06-22 2004-11-10 Univ California Nukleinsäure-gekoppelte kolorimetrische analytdetektoren
EP2360271A1 (de) 1998-06-24 2011-08-24 Illumina, Inc. Dekodierung von Arraysensoren mit Mikrosphären
US6100035A (en) * 1998-07-14 2000-08-08 Cistem Molecular Corporation Method of identifying cis acting nucleic acid elements
US20040259079A1 (en) * 1998-07-22 2004-12-23 Immusol, Inc. Substantially complete ribozyme libraries
US6399302B1 (en) * 1998-08-21 2002-06-04 University Of Virginia Patent Foundation Signal generating oligonucleotide-based biosensor
US20040242521A1 (en) * 1999-10-25 2004-12-02 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US20060172925A1 (en) * 1998-10-26 2006-08-03 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
EP1002875A1 (de) * 1998-11-17 2000-05-24 Mira Diagnostica GmbH Oligonucleotid Inhibitor von thermostabilen Polymerasen
US6927024B2 (en) * 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
US6858390B2 (en) * 1998-12-31 2005-02-22 Ingeneus Corporation Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes
MXPA01007352A (es) * 1999-01-19 2003-06-06 Somalogic Inc Metodo y aparato para la generacion automatizada de ligandos de acido nucleico.
CA2259745A1 (en) * 1999-01-19 2000-07-19 Guy Tremblay Generation of oligonucleotide libraries representative of genomes or expressed mrnas (cdnas) and use thereof
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US7189506B1 (en) 1999-03-03 2007-03-13 Genelabs Technologies, Inc. DNA binding compound-mediated molecular switch system
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030207295A1 (en) * 1999-04-20 2003-11-06 Kevin Gunderson Detection of nucleic acid reactions on bead arrays
AU4476900A (en) 1999-04-20 2000-11-02 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US20060275782A1 (en) 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US6680377B1 (en) * 1999-05-14 2004-01-20 Brandeis University Nucleic acid-based detection
US8080380B2 (en) 1999-05-21 2011-12-20 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US8481268B2 (en) 1999-05-21 2013-07-09 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US8137906B2 (en) 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
US7074586B1 (en) 1999-06-17 2006-07-11 Source Precision Medicine, Inc. Quantitative assay for low abundance molecules
US6280943B1 (en) * 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
WO2001006249A2 (en) 1999-07-02 2001-01-25 Conceptual Mindworks, Inc. Organic semiconductor recognition complex and system
US6387620B1 (en) * 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
US6506887B1 (en) * 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
BR0003768A (pt) * 1999-08-26 2001-07-03 Tomas Antonio Santa Coloma Oligocorpos monoclonais e policlonais (reagentes sintéticos semelhantes a anticorpos baseados em oligonucleotìdeos) e um método de produção dos oligocorpos
US7001723B1 (en) 1999-11-24 2006-02-21 The Research Foundation Of State University Of New York Catalytic RNAs with aminoacylation activity
US6558911B1 (en) 1999-12-10 2003-05-06 Oregon Health Sciences University Sperm quality assay
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CA2328356A1 (en) * 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
AU2001229637A1 (en) * 2000-01-21 2001-07-31 Thomas Jefferson University Nipple aspirate fluid specific microarrays
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
EP1967595A3 (de) 2000-02-16 2008-12-03 Illumina, Inc. Paralleles Genotypisieren von mehreren Patientenproben
US6500622B2 (en) 2000-03-22 2002-12-31 Quantum Dot Corporation Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
US7129326B2 (en) * 2000-04-14 2006-10-31 Genencor International, Inc. Methods for selective targeting
US20020098524A1 (en) * 2000-04-14 2002-07-25 Murray Christopher J. Methods for selective targeting
US7682837B2 (en) * 2000-05-05 2010-03-23 Board Of Trustees Of Leland Stanford Junior University Devices and methods to form a randomly ordered array of magnetic beads and uses thereof
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US7892484B2 (en) * 2000-06-30 2011-02-22 Conceptual Mindworks, Inc. Methods and compositions for neutralizing anthrax and other bioagents
US20030207271A1 (en) * 2000-06-30 2003-11-06 Holwitt Eric A. Methods and compositions for biological sensors
WO2002006827A1 (en) * 2000-07-05 2002-01-24 The General Hospital Corporation Compounds and methods for fluorescently labeling nucleic acids
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
EP2351855A1 (de) 2000-09-26 2011-08-03 Duke University RNA-Aptamere und Verfahren zu ihrer Identifizierung
DE10049074A1 (de) * 2000-10-02 2002-04-18 Andreas Kage Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren
DE10048944A1 (de) * 2000-10-03 2002-04-18 Andreas Kage Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren durch zweidimensionale Auftrennung
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
ATE536550T1 (de) 2000-10-06 2011-12-15 Life Technologies Corp Halbleiter nanokristalle enthaltende transfektibare mizellen
CA2425605A1 (en) 2000-10-16 2002-04-25 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
US20050054942A1 (en) 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
JP4379561B2 (ja) * 2001-01-30 2009-12-09 キヤノンファインテック株式会社 シート処理装置及びこれを備えた画像形成装置
US7115369B2 (en) * 2001-03-15 2006-10-03 Iowa State University Research Foundation, Inc. Functional nucleic acid probes and uses thereof
US7678554B2 (en) 2001-03-19 2010-03-16 President And Fellows Of Harvard College Nucleic acid shuffling
US7807408B2 (en) * 2001-03-19 2010-10-05 President & Fellows Of Harvard College Directed evolution of proteins
JP2004532022A (ja) * 2001-03-26 2004-10-21 サーナ・セラピューティクス・インコーポレイテッド Ｂ型肝炎ウイルスおよびｃ型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害
US7563255B2 (en) 2001-05-03 2009-07-21 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
DE10122847A1 (de) * 2001-05-11 2002-11-21 Noxxon Pharma Ag Enterotoxin B bindende Nukleinsäure
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
AU2002312059B2 (en) 2001-05-25 2009-01-15 Duke University Modulators of pharmacological agents
CN101671335A (zh) 2001-05-31 2010-03-17 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
US8030465B2 (en) 2001-06-29 2011-10-04 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
AU2775402A (en) * 2001-06-29 2003-01-02 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
EP1425408A4 (de) 2001-08-17 2004-11-10 Neose Technologies Inc Chemoenzymatische synthese sialylierter oligosaccharide
WO2003029492A1 (en) * 2001-09-28 2003-04-10 Justin Gallivan Metabolic genes and related methods and compositions
AU2002365084A1 (en) * 2001-10-19 2003-07-24 Sirna Therapeutics, Inc Method and reagent for the detection of proteins and peptides
FI115343B (fi) * 2001-10-22 2005-04-15 Filtronic Lk Oy Sisäinen monikaista-antenni
ATE469164T1 (de) 2001-10-26 2010-06-15 Noxxon Pharma Ag Modifizierte l-nukleinsäure
US20030162190A1 (en) * 2001-11-15 2003-08-28 Gorenstein David G. Phosphoromonothioate and phosphorodithioate oligonucleotide aptamer chip for functional proteomics
DK1314783T3 (da) 2001-11-22 2009-03-16 Sloning Biotechnology Gmbh Nukleinsyrelinkere og deres anvendelse i gensyntese
US20030219775A1 (en) * 2001-12-14 2003-11-27 Ward David C. Nucleic acid diagnostic reagents and methods for detecting nucleic acids, polynucleotides and oligonucleotides
WO2003051314A2 (en) 2001-12-18 2003-06-26 Medallion Biomedical, Llc Antibiotic compounds
US20040002083A1 (en) * 2002-01-29 2004-01-01 Ye Ding Statistical algorithms for folding and target accessibility prediction and design of nucleic acids
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
WO2003069333A1 (en) * 2002-02-14 2003-08-21 Illumina, Inc. Automated information processing in randomly ordered arrays
CA2476425C (en) * 2002-02-15 2012-04-17 The Research Foundation Of State University Of New York At Buffalo Ribozymes with broad trna aminoacylation activity
AU2003217580A1 (en) * 2002-02-19 2003-09-09 Syntherica Corporation Surrogate antibodies and methods of preparation and use thereof
WO2003106476A1 (en) * 2002-02-20 2003-12-24 Sirna Therapeutics, Inc Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1487343B1 (de) 2002-03-05 2008-12-31 Board of Regents, The University of Texas System Biospezifische kontrastmittel
US20030219801A1 (en) * 2002-03-06 2003-11-27 Affymetrix, Inc. Aptamer base technique for ligand identification
US20040018515A1 (en) * 2002-04-03 2004-01-29 Diener John L. Compositions selective for adenosine diphosphate and methods of using same
AU2003233243A1 (en) * 2002-05-06 2003-11-17 Noxxon Pharma Ag Method for amplifying nucleic acids
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
WO2003102212A2 (en) * 2002-05-31 2003-12-11 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
AU2003247576A1 (en) * 2002-06-18 2003-12-31 Archemix Corp. Aptamer-toxin molecules and methods for using same
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
US6989442B2 (en) * 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US7655790B2 (en) 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
CA2492463A1 (en) 2002-07-25 2004-02-05 Archemix Corporation Regulated aptamer therapeutics
AU2003251681A1 (en) * 2002-08-01 2004-02-23 Noxxon Pharma Ag Ghrelin binding nucleic acids
EP1393742A1 (de) 2002-08-14 2004-03-03 atugen AG Verwendung von Protein Kinase N beta
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
US7785799B2 (en) * 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
DE10241938A1 (de) * 2002-09-10 2004-03-25 Noxxon Pharma Ag Verfahren zur Selektion von Nukleinsäureliganden
JP2005538380A (ja) 2002-09-11 2005-12-15 ユニヴァーシティ オヴ フロリダ 神経細胞損傷の分析
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
EP2233494A3 (de) * 2002-09-20 2013-05-29 Yale University Riboswitches, Verfahren für deren Anwendung, Zusammensetzungen damit
US20040110213A1 (en) * 2002-09-30 2004-06-10 Eugeni Namsaraev Polynucleotide synthesis and labeling by kinetic sampling ligation
AU2003274011B2 (en) 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
AU2003304278B2 (en) * 2002-10-16 2009-03-12 Board Of Regents Of The University Of Texas System Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
BR0315411A (pt) 2002-10-18 2005-08-16 Atugen Ag Fator para metástase e empregos deste
GB0225833D0 (en) * 2002-11-06 2002-12-11 Univ Leeds Nucleic acid ligands and uses therefor
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
EP1585824A4 (de) 2002-11-21 2008-01-02 Epict Technologies Herstellung und verwendung einzelsträngiger transkriptionssubstrate zur synthese von zielsequenzen entsprechenden transkriptionsprodukten
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20040180360A1 (en) * 2002-11-21 2004-09-16 Charles Wilson Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
CN1774232B (zh) * 2002-11-25 2012-05-09 金克克国际有限公司 皮肤或毛发结合肽
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US6936496B2 (en) 2002-12-20 2005-08-30 Hewlett-Packard Development Company, L.P. Nanowire filament
ATE426575T1 (de) * 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
US6943768B2 (en) 2003-02-21 2005-09-13 Xtellus Inc. Thermal control system for liquid crystal cell
US6861251B2 (en) 2003-02-24 2005-03-01 Pritest, Inc. Translucent solid matrix assay device for microarray analysis
US20060211044A1 (en) * 2003-02-24 2006-09-21 Green Lawrence R Translucent solid matrix assay device dor microarray analysis
EP2290082A1 (de) 2003-03-04 2011-03-02 Intercell AG Streptococcus-pyogenes-Antigene
US7140685B2 (en) * 2003-03-11 2006-11-28 Gardner Kenneth J Swivel chair joint
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
WO2004087746A2 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
US7745607B2 (en) * 2003-03-31 2010-06-29 Mcmaster University Aptamer selection method
CN1774447B (zh) 2003-04-15 2011-04-06 英特塞尔股份公司 肺炎链球菌抗原
CA2523260A1 (en) 2003-04-21 2004-11-04 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050250106A1 (en) * 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
WO2004099411A1 (en) * 2003-05-07 2004-11-18 Novartis Ag A method for dissecting the rna secondary structure dependence of rna-ligand interactions
EP2289907A3 (de) 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae-Antigene I + II
EP1635765B1 (de) * 2003-05-23 2013-07-17 Board Of Regents, The University Of Texas System Strukturbasiertes und kombinatorisch ausgewähltes oligonucleosid-phosphorothioat und phosphorodithioat aptamer targeting ap-1 transkriptionsfaktoren
WO2004113495A2 (en) 2003-05-23 2004-12-29 The President And Fellows Of Harvard College Rna-based transcriptional regulators
EP1635693A2 (de) * 2003-05-23 2006-03-22 Board Of Regents, The University Of Texas System Screening mit hohem durchsatz von aptamer-bibliotheken für die spezifische bindung an proteine auf viren und anderen erregern
DE10325152B4 (de) * 2003-05-30 2011-07-21 Kage, Andreas, Dr., 12207 Verfahren zur quantitativen Bestimmung einer unbekannten Menge einer Zielmolekülspezies
US20050250094A1 (en) * 2003-05-30 2005-11-10 Nanosphere, Inc. Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes
US20080175856A1 (en) 2003-05-30 2008-07-24 Intercell Ag Enterococcus Antigens
CN1279056C (zh) * 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5－1的特异性抗体及其应用
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
EP1493810A1 (de) 2003-06-30 2005-01-05 Gentium S.p.A. Auf DNA-basierte Aptamere für Cathepsin G
US20050112100A1 (en) 2003-07-10 2005-05-26 Michigan State University Sp1 and Sp3 targeted cancer therapies and therapeutics
WO2005010016A2 (en) * 2003-07-24 2005-02-03 Board Of Regents Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
WO2005012487A2 (en) 2003-08-01 2005-02-10 Invitrogen Corporation Compositions and methods for preparing short rna molecules and other nucleic acids
US20050043245A1 (en) * 2003-08-11 2005-02-24 Siler -Khodr Theresa M. Non-mammalian GnRH analogs and uses thereof in the immune system
CA2535799A1 (en) 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7329742B2 (en) 2003-09-04 2008-02-12 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
US20050064435A1 (en) * 2003-09-24 2005-03-24 Xing Su Programmable molecular barcodes
CA2540407A1 (en) * 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
CA2540472A1 (en) * 2003-09-30 2005-04-07 The Hospital For Sick Children Method of in situ detection of proteins using aptamers
US7803624B2 (en) 2003-09-30 2010-09-28 Cytyc Corporation Automated cytological sample classification
US7625707B2 (en) * 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
US7223611B2 (en) * 2003-10-07 2007-05-29 Hewlett-Packard Development Company, L.P. Fabrication of nanowires
US7132298B2 (en) * 2003-10-07 2006-11-07 Hewlett-Packard Development Company, L.P. Fabrication of nano-object array
KR20060125743A (ko) * 2003-11-10 2006-12-06 녹손 파르마 아게 생체 활성형 그렐린에 특이적으로 결합하는 핵산
EP1689445B1 (de) 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
WO2005051174A2 (en) * 2003-11-21 2005-06-09 The Trustees Of Columbia University In The City Of New York Nucleic acid aptamer-based compositions and methods
GB0328448D0 (en) * 2003-12-09 2004-01-14 Univ Leeds Agents for the regulation of transcription via zinc finger proteins
US20050123932A1 (en) * 2003-12-09 2005-06-09 Mekbib Astatke Nucleic acid-chelating agent conjugates
CA2545006C (en) * 2003-12-12 2013-09-17 Saint Louis University Biosensors for detecting macromolecules and other analytes
US7361410B2 (en) * 2003-12-29 2008-04-22 Intel Corporation External modification of composite organic inorganic nanoclusters comprising raman active organic compound
US20050191665A1 (en) * 2003-12-29 2005-09-01 Xing Su Composite organic-inorganic nanoclusters
US20080076119A9 (en) * 2003-12-29 2008-03-27 Lei Sun Composite organic inorganic nanoclusters
US20050147963A1 (en) * 2003-12-29 2005-07-07 Intel Corporation Composite organic-inorganic nanoparticles and methods for use thereof
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP1727567B1 (de) 2004-02-12 2013-07-03 Archemix LLC Zur Behandlung von Erkrankungen in Verbindung mit dem Komplementsystem geeignete Aptamer-Therapeutika
US8318920B2 (en) * 2004-02-27 2012-11-27 Operational Technologies Corporation Therapeutic nucleic acid-3′-conjugates
US7910297B2 (en) * 2004-02-27 2011-03-22 Operational Technologies Corporation Therapeutic nucleic acid-3' -conjugates
US8389710B2 (en) 2004-02-27 2013-03-05 Operational Technologies Corporation Therapeutic nucleic acid-3′-conjugates
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
AU2005220910A1 (en) * 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
EP1734941A2 (de) 2004-03-25 2006-12-27 The Feinstein Institute for Medical Research Neurale staubinde
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7407738B2 (en) * 2004-04-02 2008-08-05 Pavel Kornilovich Fabrication and use of superlattice
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8470315B2 (en) 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
US20050239134A1 (en) * 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
PT1745062E (pt) * 2004-04-22 2014-07-11 Regado Biosciences Inc Moduladores melhorados de fatores de coagulação
US7579450B2 (en) * 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
DE102004021707A1 (de) * 2004-04-30 2005-11-24 Cytotools Gmbh Verfahren zur Isolierung von spezifischen Molekülen, die hochselektiv an ausgewählte Zielmoleküle binden
US7683435B2 (en) 2004-04-30 2010-03-23 Hewlett-Packard Development Company, L.P. Misalignment-tolerant multiplexing/demultiplexing architectures
US7247531B2 (en) 2004-04-30 2007-07-24 Hewlett-Packard Development Company, L.P. Field-effect-transistor multiplexing/demultiplexing architectures and methods of forming the same
US20060024814A1 (en) * 2004-07-29 2006-02-02 Peters Kevin F Aptamer-functionalized electrochemical sensors and methods of fabricating and using the same
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US20070048797A1 (en) * 2004-08-11 2007-03-01 Xing Su Composite organic inorganic nanoclusters as carriers and identifiers of tester molecules
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
US20060040258A1 (en) * 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
WO2006033766A2 (en) * 2004-08-25 2006-03-30 The Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
US7776547B2 (en) * 2004-08-26 2010-08-17 Intel Corporation Cellular analysis using Raman surface scanning
US20060046311A1 (en) * 2004-08-26 2006-03-02 Intel Corporation Biomolecule analysis using Raman surface scanning
EP1789096A4 (de) * 2004-09-07 2009-07-08 Archemix Corp Aptamere für den von-willebrand-faktor und ihre verwendung als therapeutika für thrombotische erkrankungen
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070101226A (ko) * 2004-09-07 2007-10-16 아케믹스 코포레이션 앱타머의 약화학
WO2006027780A2 (en) * 2004-09-08 2006-03-16 Ramot At Tel Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
US7659091B2 (en) 2004-09-21 2010-02-09 Nourheart, Inc. Diagnostic marker
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US8293253B2 (en) * 2004-10-28 2012-10-23 Idexx Laboratories, Inc. Compositions for controlled delivery of pharmaceutically active compounds
EP2436391A3 (de) 2004-11-02 2012-07-04 Archemix LLC Stabilisierte Aptamere für einen aus Plättchen gewonnenen Wachstumsfaktor und ihre Verwendung als Krebstherapiemittel
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
ES2548515T3 (es) 2004-12-27 2015-10-19 Silence Therapeutics Gmbh Complejos lipídicos recubiertos con PEG y su uso
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CN102793972A (zh) 2004-12-27 2012-11-28 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病
US20060147941A1 (en) * 2004-12-30 2006-07-06 Intel Corporation Methods and apparatus for SERS assay of biological analytes
US9505846B2 (en) * 2005-01-28 2016-11-29 Life Technologies Corporation Multi-component inhibitors of nucleic acid polymerases
US7375012B2 (en) * 2005-02-28 2008-05-20 Pavel Kornilovich Method of forming multilayer film
WO2006094014A2 (en) 2005-02-28 2006-09-08 The Regents Of The University Of California Methods for diagnosis and treatment of endometrial cancer
CA2600418A1 (en) * 2005-03-07 2006-09-14 Archemix Corp. Stabilized aptamers to psma and their use as prostate cancer therapeutics
JP2008535796A (ja) 2005-03-10 2008-09-04 ジェネンテック・インコーポレーテッド 脈管の完全性を調節するための方法及び組成物
US20060205090A1 (en) * 2005-03-14 2006-09-14 Newton Michael W Water-soluble conjugates for electrochemical detection
WO2006102540A2 (en) * 2005-03-24 2006-09-28 Syracuse University Elucidation of high affinity, high specificity oligonucleotides and derivatized oligonucleotide sequences for target recognition
US20100036106A1 (en) * 2005-03-30 2010-02-11 Nec Soft, Ltd. High-Affinity RNA Aptamer Molecule Against Glutathione-S-Transferase Protein
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
DE102005022057B3 (de) * 2005-05-09 2007-02-08 Analyticon Biotechnologies Ag Verfahren zur Herstellung von Liganden, Liganden und Test-Kit
US20060281702A1 (en) * 2005-05-18 2006-12-14 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate aptamers for RNases
US7795009B2 (en) * 2005-06-15 2010-09-14 Saint Louis University Three-component biosensors for detecting macromolecules and other analytes
US8956857B2 (en) 2005-06-06 2015-02-17 Mediomics, Llc Three-component biosensors for detecting macromolecules and other analytes
CA2611198C (en) 2005-06-10 2015-04-28 Saint Louis University Methods for the selection of aptamers
US7811809B2 (en) * 2005-06-15 2010-10-12 Saint Louis University Molecular biosensors for use in competition assays
WO2007005426A2 (en) * 2005-06-29 2007-01-11 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
KR20080025181A (ko) 2005-06-30 2008-03-19 아케믹스 코포레이션 완전 2'-변형된 핵산 전사체를 생성하기 위한 물질 및 방법
EP1918372A4 (de) 2005-07-05 2009-08-12 Ribomic Inc Zur bindung an immunglobulin g fähige nukleinsäure und verwendung davon
US7662571B2 (en) 2005-07-14 2010-02-16 Nourheart Inc. Mitochondrial markers of ischemia
US20100254901A1 (en) * 2005-07-28 2010-10-07 Smith Cassandra L Compositions comprising nucleic acid aptamers
US20070041934A1 (en) * 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168402B2 (en) * 2005-11-03 2012-05-01 Lohocla Research Corporation Diagnostic tests of substance use disorders
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
CA2628451A1 (en) 2005-11-04 2007-05-18 Biogen Idec Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
US8017159B2 (en) * 2005-11-16 2011-09-13 Idexx Laboratories, Inc. Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
JP5119444B2 (ja) * 2005-12-06 2013-01-16 国立大学法人 東京大学 多目的アシル化触媒とその用途
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
CN101395180B (zh) 2005-12-30 2016-06-22 赢创罗姆有限责任公司 用作细胞穿膜肽的肽
US20070155022A1 (en) * 2005-12-30 2007-07-05 Mineo Yamakawa Degenerate binding detection and protein identification using Raman spectroscopy nanoparticle labels
US20070239483A1 (en) * 2006-01-09 2007-10-11 Biophysical Corporation Methods for individualized health assessment service
CA2636855C (en) 2006-01-11 2016-09-27 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
TWI507528B (zh) 2006-01-17 2015-11-11 Somalogic Inc 測試樣品的多重分析方法
EP1981902B1 (de) 2006-01-27 2015-07-29 Biogen MA Inc. Nogo-rezeptorantagonisten
US7922000B2 (en) * 2006-02-15 2011-04-12 Miraial Co., Ltd. Thin plate container with a stack of removable loading trays
US8460878B2 (en) 2006-02-21 2013-06-11 The Trustees Of Tufts College Methods and arrays for detecting cells and cellular components in small defined volumes
RU2477137C2 (ru) 2006-03-08 2013-03-10 АРКЕМИКС Эл Эл Си Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
US8097425B2 (en) * 2006-03-10 2012-01-17 Tethys Bioscience, Inc. Multiplex protein fractionation
JP4984990B2 (ja) * 2006-03-28 2012-07-25 富士通株式会社 機能性分子の製造方法
US20070231855A1 (en) * 2006-03-28 2007-10-04 Fujitsu Limited Functional molecule and manufacturing method therefor
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
CA2649630C (en) 2006-04-20 2016-04-05 Silence Therapeutics Ag Lipoplex formulations for specific delivery to vascular endothelium
US20080020475A1 (en) * 2006-05-05 2008-01-24 Rules-Based Medicine, Inc Methods and kits for the diagnosis of hypothyroidism
EP2047910B1 (de) 2006-05-11 2012-01-11 Raindance Technologies, Inc. Mikrofluidische Vorrichtung und Verfahren
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
DE202006007590U1 (de) 2006-05-12 2006-12-14 Osaka University Verwendung einer Zusammensetzung, die Sema7A- und VLA-1-Interaktion inhibiert, zum Behandeln von Cytokin-vermittelten Erkrankungen
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US20070292397A1 (en) * 2006-06-19 2007-12-20 Mcnulty Amy K Method for the detection and neutralization of bacteria
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
JP2009541333A (ja) 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
JP2009543868A (ja) 2006-07-17 2009-12-10 クインテセンス バイオサイエンシーズ インコーポレーティッド 癌治療に関する方法および組成物
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
KR101670085B1 (ko) 2006-07-21 2016-10-28 사일런스 테라퓨틱스 게엠베하 단백질 키나아제 3의 발현을 억제하기 위한 수단
US7645582B2 (en) * 2006-07-21 2010-01-12 Hitachi Chemical Co., Ltd. Aptamers that bind to listeria surface proteins
WO2008011608A2 (en) * 2006-07-21 2008-01-24 Hitachi Chemical Co., Ltd. Nucleic acid ligands capable of binding to internalin b or internalin a
US20080031903A1 (en) * 2006-07-27 2008-02-07 Andrea Gambotto Method of treating ocular infections
CA2658105C (en) * 2006-08-01 2016-07-05 Gen-Probe Incorporated Methods of nonspecific target capture of nucleic acids
EP2048246B1 (de) 2006-08-03 2011-09-14 NEC Soft, Ltd. Verfahren zur gewinnung eines oligonukleotids
EP2077912B1 (de) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorkohlenstoffemulsionsstabilisierende tenside
US20080070802A1 (en) * 2006-08-23 2008-03-20 Moerschell Richard P Directed heterobifunctional linkers
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
US20100136537A1 (en) * 2006-10-10 2010-06-03 The Regents Of The University Of Michigan Photoreceptor precursor cells
JP4841396B2 (ja) 2006-10-18 2011-12-21 Ｎｅｃソフト株式会社 塩基配列の同定装置、核酸分子の二次構造取得装置、塩基配列の同定方法、核酸分子の二次構造取得方法、プログラム及び記録媒体
EP1913955A1 (de) 2006-10-19 2008-04-23 Gerhard, Markus Neue Methode zur Behandlung von Infektionen durch H. pylori
US7598040B2 (en) 2006-11-22 2009-10-06 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
MX2009006779A (es) 2006-12-19 2009-08-27 Genentech Inc Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
WO2008089059A1 (en) * 2007-01-12 2008-07-24 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of galactosemia
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) * 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US20110136099A1 (en) * 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8586303B1 (en) 2007-01-22 2013-11-19 Steven Albert Benner In vitro selection with expanded genetic alphabets
US9725713B1 (en) 2007-01-22 2017-08-08 Steven A Benner In vitro selection with expanded genetic alphabets
WO2008092041A2 (en) 2007-01-24 2008-07-31 Carnegie Mellon University Optical biosensors
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
EP2134830A2 (de) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oszillations-zellkultur-bioreaktor
US20080255766A1 (en) * 2007-02-16 2008-10-16 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of sickle cell
DE102007011702A1 (de) 2007-03-08 2008-09-11 Rheinische Friedrich-Wilhelms Universität Aptamer-basierte Reagenzien
US20100197510A1 (en) * 2007-03-08 2010-08-05 Michael Spain Methods for rapid disease screening
EP2132339B1 (de) * 2007-04-04 2011-03-09 Chimera Biotec GmbH Verfahren zum nachweis eines analyten in einer biologischen matrix
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
US20080248958A1 (en) * 2007-04-05 2008-10-09 Hollenbach Andrew D System for pulling out regulatory elements in vitro
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
AU2008275501A1 (en) * 2007-04-19 2009-01-15 The Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
JP5214723B2 (ja) 2007-04-30 2013-06-19 ナノゲン・インコーポレイテッド 多分析物アッセイ
EP2489673A3 (de) 2007-05-02 2012-09-12 Intercell AG Klebsiella-Antigene
CN101883782A (zh) 2007-06-18 2010-11-10 英特塞尔股份公司 衣原体抗原
EP2933340B1 (de) 2007-07-17 2017-09-06 Somalogic, Inc. Aptamere mit an der 5-Position mit einer Benzylgruppe substituiertem Uridin und/oder Thymidin
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
FR2920024B1 (fr) 2007-08-14 2012-12-14 Lfb Biotechnologies Procede de purification ou de detection d'une proteine cible
WO2009026540A1 (en) * 2007-08-22 2009-02-26 Colorado School Of Mines Lanthanide nanoparticle conjugates and uses thereof
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
DE102007041476B4 (de) 2007-08-31 2017-03-30 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamere, die an ein an der Hämostase beteiligtes Zielmolekül binden
US8198039B2 (en) * 2007-09-04 2012-06-12 University of Pittsburgh—of the Commonwealth System of Higher Education Biosensors and related methods
WO2009033027A2 (en) 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
US20090068669A1 (en) * 2007-09-12 2009-03-12 Elias Georges Slc9a3r1 directed diagnostics for neoplastic disease
CN101854938B (zh) * 2007-09-14 2013-06-12 北卡罗来纳州立大学 鉴别反转录病毒感染抑制剂的组合物和方法
US20090094716A1 (en) * 2007-09-24 2009-04-09 Performance Plants, Inc. Plants having increased biomass
EP2197454A4 (de) * 2007-09-25 2012-07-04 Idexx Lab Inc Pharmazeutische zusammensetzungen zur verabreichung von oligonucleotiden
SG188082A1 (en) 2007-10-02 2013-03-28 Theranos Inc Modular point-of-care devices and uses thereof
US9200382B2 (en) * 2007-10-05 2015-12-01 The Regents Of The University Of California High-stringency screening of target-binding partners using a microfluidic device
EP2045326A1 (de) * 2007-10-05 2009-04-08 Bayer CropScience AG Verfahren zum Identifizieren des Interaktionspartners eines Wirkstoffes
EP2205271B1 (de) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Zusammensetzungen und verfahren für therapien auf ribonukleasebasis
ES2627292T3 (es) 2007-10-12 2017-07-27 Massachusetts Institute Of Technology Nanotecnología de vacunas
US20090163437A1 (en) * 2007-10-16 2009-06-25 Regado Biosciences, Inc. Steady-state subcutaneous administration of aptamers
EP2209914B2 (de) † 2007-10-22 2017-07-26 Caris Life Sciences Switzerland Holdings GmbH Verfahren zur auswahl von aptameren
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
WO2009064424A1 (en) * 2007-11-13 2009-05-22 Rational Affinity Devices, L.L.C. Tunable affinity ligands for the separation and detection of target substances
EP2268664B1 (de) 2007-12-03 2017-05-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Doc1-zusammensetzungen und verfahren zur behandlung von krebs
ES2916498T3 (es) 2007-12-06 2022-07-01 Genalyte Inc Método para identificar una secuencia de nucleótidos en una especie desconocida de ácido nucleico; y dispositivo para llevar a cabo el método
US8865401B2 (en) 2007-12-14 2014-10-21 The Johns Hopkins University Purification and concentration of proteins and DNA from a complex sample using isotachophoresis and a device to perform the purification
WO2009078939A1 (en) * 2007-12-17 2009-06-25 Brown University Methods for identifying nucleotide ligands
JP5550182B2 (ja) 2008-01-07 2014-07-16 ルミネックス コーポレーション 複合試料マトリクスからの細胞の単離および計数の方法
WO2009089062A2 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
EP2245466A2 (de) 2008-02-04 2010-11-03 Banyan Biomarkers, Inc. Verfahren zur diagnose oder behandlung einer gehirnverletzung
CN102066562A (zh) * 2008-03-12 2011-05-18 雪城大学 结构限定的适配子的直接选择
WO2009151687A2 (en) 2008-03-12 2009-12-17 The Regents Of The University Of Michigan Dendrimer conjugates
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9115352B2 (en) 2008-03-31 2015-08-25 Sloning Biotechnology Gmbh Method for the preparation of a nucleic acid library
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
EP2285953B1 (de) 2008-05-02 2015-01-14 Cellscript, Llc Rna-polyphosphatasezusammensetzungen, kits und ihre verwendung
WO2009137095A2 (en) 2008-05-08 2009-11-12 The Johns Hopkins University Compositions and methods for modulating an immune response
US20120003749A1 (en) * 2008-05-21 2012-01-05 Nec Soft, Ltd. Nucleic acid molecule capable of binding to 2,4,6-trinitrophenyl skeleton, method for detecting compound having 2,4,6-trinitrophenyl skeleton using the nucleic acid molecule, and use of the nucleic acid molecule
DK2297313T3 (en) 2008-06-06 2015-06-08 Danisco Us Inc ALPHA AMYLASE VARIETIES OF BACILLUS SUBTILIS AND METHODS OF USING IT
US8722638B2 (en) * 2008-06-20 2014-05-13 Children's Medical Center Corporation Methods for the modulation of angiogenesis
ES2602119T3 (es) 2008-07-14 2017-02-17 The University Of Tokyo Aptámero contra IL-17 y uso del mismo
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
EP2338051B1 (de) 2008-07-17 2013-11-20 IKFE Institut für klinische Forschung und Entwicklung GmbH Biomarker für kardiodiabetes
AU2009270682B2 (en) 2008-07-17 2016-04-21 Ikfe Lnstitut Fur Klinische Forschung Und Entwicklung Gmbh Biomarkers for insulin resistance and beta-cell dysfunction
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US8968705B2 (en) 2008-08-22 2015-03-03 Colorado School Of Mines Gold/lanthanide nanoparticle conjugates and uses thereof
US20100068729A1 (en) * 2008-09-12 2010-03-18 Rules-Based Medicine, Inc. Method and kits for the diagnosis of diabetes
HUE026595T2 (hu) 2008-09-24 2016-06-28 Ribomic Inc Aptamer NGF-hez és alkalmazása
US20110229920A1 (en) * 2008-09-29 2011-09-22 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
US8889635B2 (en) 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
EP2334695B1 (de) 2008-10-01 2015-12-23 Quintessence Biosciences, Inc. Therapeutische ribonukleasen
US9173840B2 (en) 2008-10-09 2015-11-03 Northeastern University Multifunctional self-assembling polymeric nanosystems
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
EP2340040B1 (de) 2008-10-22 2019-01-16 F.Hoffmann-La Roche Ag Modulierung von axonen-degeneration
EP2347247B1 (de) 2008-10-27 2019-06-26 Genalyte, Inc. Auf optischer sondierung und optischem abtasten basierende biosensoren
WO2010051105A1 (en) 2008-10-29 2010-05-06 China Synthetic Rubber Corporation Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
WO2010096126A1 (en) 2008-10-29 2010-08-26 Bg Medicine, Inc. Galectin-3 immunoassay
WO2010054321A2 (en) 2008-11-07 2010-05-14 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
WO2010059617A2 (en) 2008-11-18 2010-05-27 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
WO2010059820A1 (en) 2008-11-21 2010-05-27 Saint Louis University Biosensor for detecting multiple epitopes on a target
CA2782776A1 (en) 2008-12-04 2010-06-10 Ikfe Gmbh Biomarkers for atherosclerosis
US20110118134A1 (en) 2008-12-11 2011-05-19 Ikfe Gmbh Biomarkers for insulin sensitizer drug response
CA2688174C (en) 2008-12-19 2018-08-07 F. Hoffmann-La Roche Ag Dry composition of reaction compounds with stabilized polymerase
US20100209350A1 (en) 2008-12-30 2010-08-19 Andreas Pfuetzner Biomarkers for Adipose Tissue Activity
WO2010079428A2 (en) 2009-01-07 2010-07-15 Ikfe Gmbh Biomarkers for appetite regulation
BRPI1008745A2 (pt) 2009-02-05 2019-09-17 Tokai Pharmaceuticals Inc pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
DK3912643T3 (da) 2009-02-13 2022-10-17 Immunomedics Inc Immunokonjugater med en intracellulært-spaltelig binding
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
EP2398860B1 (de) 2009-02-18 2013-11-20 Carnegie Mellon University Gelöschte dendrimere farbstoffe zur fluoreszenzdetektion
FR2942232B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine de la coagulation et procedes pour sa mise en oeuvre
WO2010104959A1 (en) 2009-03-11 2010-09-16 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
US10702583B2 (en) 2009-03-11 2020-07-07 Promedior, Inc. Treatment methods for autoimmune disorders
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
JP5561755B2 (ja) 2009-04-01 2014-07-30 Ｎｅｃソリューションイノベータ株式会社 Ｓｅｌｅｘ法用のプライマーの設計方法、プライマーの製造方法、アプタマーの製造方法、プライマーの設計装置、プライマー設計用コンピュータプログラムおよび記録媒体
WO2010118435A2 (en) 2009-04-10 2010-10-14 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
WO2010128016A2 (en) 2009-05-04 2010-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Par2 agonists for use in the treatment or prevention of influenza virus type a infections
BRPI1011269A2 (pt) * 2009-05-05 2016-09-27 Altermune Technologies Llc imunidade quimicamente programável
US20100291706A1 (en) 2009-05-15 2010-11-18 Millipore Corporation Dye conjugates and methods of use
KR20120016297A (ko) 2009-06-01 2012-02-23 코넬 유니버시티 미소구를 이용한 통합 광학유체 시스템
SG176644A1 (en) 2009-06-03 2012-01-30 Regado Biosciences Inc Nucleic acid modulators of glycoprotein vi
WO2010141928A2 (en) 2009-06-05 2010-12-09 University Of Florida Research Foundation, Inc. Isolation and targeted suppression of lignin biosynthetic genes from sugarcane
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
AR077049A1 (es) 2009-06-11 2011-07-27 Otsuka Pharma Co Ltd Aptamero contra quimasa y su uso
CA2766057A1 (en) 2009-06-19 2010-12-23 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
ES2677564T3 (es) 2009-06-19 2018-08-03 Inserm (Institut National De La Santé Et De La Recherche Medicale) Método y composición farmacéutica para su uso en el tratamiento de trastornos neurodegenerativos
EP2445334A1 (de) 2009-06-26 2012-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Nicht humane tiermodelle für verbesserten netzhautgefässpermeabilität
AU2013203588C1 (en) * 2009-07-09 2016-06-30 Somalogic Operating Co., Inc. Method for generating aptamers with improved off-rates
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
GB0913258D0 (en) 2009-07-29 2009-09-02 Dynex Technologies Inc Reagent dispenser
US9523701B2 (en) 2009-07-29 2016-12-20 Dynex Technologies, Inc. Sample plate systems and methods
FR2948665B1 (fr) 2009-07-31 2011-09-23 Lfb Biotechnologies Procede pour la purification de proteines de la coagulation a domaine gla actives
FR2948664B1 (fr) 2009-07-31 2013-11-01 Lfb Biotechnologies Procede pour la purification de proteines de la coagulation a domaine gla
US9250234B2 (en) 2011-01-19 2016-02-02 Ohmx Corporation Enzyme triggered redox altering chemical elimination (E-TRACE) immunoassay
JP5352742B2 (ja) * 2009-08-07 2013-11-27 オームクス コーポレーション 酵素による酸化還元変化化学的脱離（ｅ−ｔｒａｃｅ）免疫学的検定法
GB0914318D0 (en) 2009-08-14 2009-09-30 Medical Res Council Method
US9024766B2 (en) * 2009-08-28 2015-05-05 The Invention Science Fund, Llc Beverage containers with detection capability
US8810417B2 (en) * 2009-08-28 2014-08-19 The Invention Science Fund I, Llc Beverage immersate with detection capability
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
WO2011023824A2 (en) 2009-08-31 2011-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Estrogen receptor modulators for the treatment of diseases involving plasmacytoid dendritic cells
HUE040281T2 (hu) 2009-09-14 2019-03-28 Banyan Biomarkers Inc Autoantitest markerek traumás agysérülés diagnózisára
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
US8945508B2 (en) 2009-10-13 2015-02-03 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
EP3011970A3 (de) 2009-10-22 2016-06-08 F. Hoffmann-La Roche AG Modulation der axondegeneration
WO2011059586A2 (en) 2009-10-30 2011-05-19 The Regents Of The University Of Michigan Multifunctional small molecules
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
WO2011054916A1 (en) 2009-11-06 2011-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of atherosclerosis
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP3348277A1 (de) 2009-11-20 2018-07-18 The Regents of The University of California Epithelialmembranenprotein-2 (emp2) und proliferative vitreoretinopathie (pvr)
WO2011061340A1 (en) 2009-11-23 2011-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity
DE102009056945A1 (de) 2009-12-07 2011-06-16 Christian-Albrechts-Universität Zu Kiel DNA-Aptamere, die den löslichen Interleukin-6-Rezeptor spezifisch binden
DE102009056944A1 (de) 2009-12-07 2011-06-09 Christian-Albrechts-Universität Zu Kiel RNA-Aptamere, die den löslichen Interleukin-6-Rezeptor spezifisch binden
WO2011079309A2 (en) 2009-12-23 2011-06-30 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
PT2523661T (pt) 2010-01-15 2017-06-21 Inserm (Institut Nat De La Santé Et De La Rech Médicale) Inibidores de nkcc para o tratamento de autismo
DE112011100297B4 (de) 2010-01-20 2017-08-24 New England Biolabs, Inc. Zusammensetzungen, Verfahren und damit in Zusammenhang stehende Anwendungen zum Spalten modifizierter DNA
US20110201076A1 (en) 2010-01-22 2011-08-18 Colorado School Of Mines Harvesting micro algae
EP2533798A2 (de) 2010-02-09 2012-12-19 Universität Bremen P19arf, hmga2 und mdm2 zur diagnose und behandlung des wachstums von anomalen zellen
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
EP2534267B1 (de) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digitale analyse von analyten
US8772259B2 (en) 2010-02-12 2014-07-08 Ribomic Inc. Aptamer to FGF2 and use thereof
WO2011100561A1 (en) 2010-02-12 2011-08-18 Saint Louis University Molecular biosensors capable of signal amplification
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US8236574B2 (en) 2010-03-01 2012-08-07 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US9678068B2 (en) 2010-03-01 2017-06-13 Quanterix Corporation Ultra-sensitive detection of molecules using dual detection methods
ES2544635T3 (es) 2010-03-01 2015-09-02 Quanterix Corporation Métodos para extender el rango dinámico en ensayos para la detección de moléculas o partículas
EP2542266A4 (de) 2010-03-03 2013-10-23 Somalogic Inc Aptamere für 4-1bb und ihre verwendung bei der behandlung von krankheiten und leiden
WO2011113118A1 (en) 2010-03-19 2011-09-22 Katholieke Universiteit Leuven Drug tolerance/persistence of fungal biofilms
WO2011118682A1 (ja) 2010-03-24 2011-09-29 株式会社リボミック Ｎｇｆに対するアプタマー及びその使用
US20130029362A1 (en) 2010-04-01 2013-01-31 Andreas Jeromin Markers and assays for detection of neurotoxicity
NZ602845A (en) 2010-04-08 2015-05-29 Inst Nat Sante Rech Med Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
SG2014006522A (en) 2010-04-12 2014-03-28 Somalogic Inc 5-position modified pyrimidines and their use
EP2577309B1 (de) 2010-05-25 2016-11-23 Carnegie Mellon University Gezielte sonden für zellphysiologie
US20130116129A1 (en) 2010-07-01 2013-05-09 National Institute Of Advanced Industrial Science And Technology Method for detecting target molecules
US9454642B2 (en) 2010-07-02 2016-09-27 Nec Solution Innovators, Ltd. Prediction device, prediction method, program, and recording medium
JP5886283B2 (ja) 2010-07-15 2016-03-16 アドヘロン セラピューティクス，インコーポレイテッド カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012019991A1 (en) 2010-08-09 2012-02-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of hiv-1 infections
EP2603607B1 (de) 2010-08-11 2016-04-06 Celula, Inc. Dns genotypisierung
WO2012021913A1 (en) 2010-08-18 2012-02-23 University Of Graz Methods for increasing resistance of plants to drought, salt and pathogens
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
WO2012038448A1 (en) 2010-09-21 2012-03-29 Riboxx Gmbh Method for synthesizing rna using dna template
EP3029153B1 (de) 2010-09-27 2018-08-01 Somalogic, Inc. Biomarker für mesotheliome und verwendungen davon
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
WO2012051519A2 (en) 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
EA026309B1 (ru) 2010-10-14 2017-03-31 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Нуклеиново-кислотные модуляторы clec-2
CA3060724A1 (en) 2010-11-05 2012-05-10 Genalyte, Inc. Optical analyte detection systems and methods of use
US9072766B2 (en) 2010-11-18 2015-07-07 Beth Israel Deaconess Medical Center, Inc. Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
US20140056811A1 (en) 2010-12-27 2014-02-27 Compugen Ltd. New cell-penetrating peptides and uses thereof
KR102080142B1 (ko) 2011-01-10 2020-02-21 아프타리온 바이오테크 아게 목표 분자에 결합력을 갖는 ｌ-형 핵산 및 이를 제조하는 방법
TWI690594B (zh) 2011-01-21 2020-04-11 美商賽瑞諾斯Ｉｐ有限責任公司 樣本使用最大化之系統及方法
WO2012107728A2 (en) 2011-02-09 2012-08-16 Cancer Research Technology Limited Frmd4a antagonists and their uses
EP2673614B1 (de) 2011-02-11 2018-08-01 Raindance Technologies, Inc. Verfahren zur bildung gemischter tröpfchen
EP2675819B1 (de) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
EP2696898A4 (de) 2011-04-07 2014-10-01 Univ Emory Zusammensetzungen mit saccharidbindenden teilen und verfahren für eine gezielte therapie
EP2704688B1 (de) 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Cochleatzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
WO2012152711A1 (en) 2011-05-06 2012-11-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for identifying aptamers
EP2707094B1 (de) 2011-05-09 2016-02-03 Setpoint Medical Corporation Einzelimpulsaktivierung des cholinergen entzündungshemmenden pfades zur behandlung chronischer entzündungen
WO2012155134A2 (en) 2011-05-12 2012-11-15 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
EP2710381A2 (de) 2011-05-16 2014-03-26 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren zum überprüfen auf zur modulation der replikation eines influenzavirus fähige substanzen
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
GB201110371D0 (en) 2011-06-17 2011-08-03 Proteome Sciences R & D Gmbh & Co Kg Materials and methods for determining sensitivity potential of compounds
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013014073A1 (en) 2011-07-22 2013-01-31 Universite De Strasbourg Phospholipid-detergent conjugates and uses thereof
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
AU2012295913A1 (en) 2011-08-12 2014-03-13 Tagcyx Biotechnologies Production method for nucleic acid aptamer
GB201114662D0 (en) 2011-08-24 2011-10-12 Altermune Technologies Llc Chemically programmable immunity
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
WO2013034687A1 (en) 2011-09-09 2013-03-14 Universität Bern Verwaltungsdirektion Avibacterium paragallinarum rtx toxin
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US8435738B2 (en) 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
WO2013040577A1 (en) 2011-09-16 2013-03-21 The Research Foundation Of State University Of New York Aptamers resistant to nucleocapsid degradation
CA2846630A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
JP6118724B2 (ja) 2011-09-28 2017-04-19 株式会社リボミック Ｎｇｆに対するアプタマー及びその用途
JP2014528411A (ja) 2011-09-30 2014-10-27 マリンクロッド エルエルシー 相補的オリゴヌクレオチドリンカーを用いる標的化ナノ粒子の遠隔アセンブリ
WO2013050540A1 (en) 2011-10-05 2013-04-11 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
EP2768967B1 (de) 2011-10-17 2017-12-06 Ohmx Corporation Einzelner direkter nachweis von hämoglobin-a1c-prozentsätzen unter verwendung eines enzymgetriggerten redox-verändernden e-trace-immunoassays
US9265817B2 (en) 2011-10-28 2016-02-23 Patrys Limited PAT-LM1 epitopes and methods for using same
WO2013065016A1 (en) 2011-11-02 2013-05-10 University Of Cape Town A method of detecting and/or quantifying an analyte in a biological sample
US9340567B2 (en) 2011-11-04 2016-05-17 Ohmx Corporation Chemistry used in biosensors
SG11201402402SA (en) 2011-11-18 2014-09-26 Tagcyx Biotechnologies Nucleic acid fragment binding to target protein
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
US20140294840A1 (en) 2011-11-30 2014-10-02 University Of Bremen Expression of mirnas in placental tissue
WO2013085718A1 (en) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Multifunctional small molecules
JP6276706B2 (ja) 2012-01-09 2018-02-07 オームクス コーポレイション Ｅ−ｔｒａｃｅアッセイシグナル増幅の酵素カスケード方法
KR102138106B1 (ko) 2012-01-31 2020-07-28 더유니버시티오브톨레도 피분석물을 검출 및 측정하기 위한 방법 및 장치
US9737480B2 (en) 2012-02-06 2017-08-22 President And Fellows Of Harvard College ARRDC1-mediated microvesicles (ARMMs) and uses thereof
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
EP2825885B1 (de) 2012-03-12 2021-05-12 The Board of Trustees of the University of Illinois Optische analytdetektionssysteme mit magnetischer verstärkung
WO2013142255A2 (en) 2012-03-22 2013-09-26 University Of Miami Multi-specific binding agents
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2015521041A (ja) 2012-05-16 2015-07-27 サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｋｎ３阻害剤投与のためのバイオマーカーとしてのｖｅｇｆｒ１の使用
WO2013177426A2 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
IN2014KN02647A (de) 2012-06-07 2015-05-08 Somalogic Inc
US9144488B2 (en) 2012-06-13 2015-09-29 Elwha Llc Breast implant with analyte sensors responsive to external power source
US9211185B2 (en) 2012-06-13 2015-12-15 Elwha Llc Breast implant with analyte sensors and internal power source
US8790400B2 (en) 2012-06-13 2014-07-29 Elwha Llc Breast implant with covering and analyte sensors responsive to external power source
US8795359B2 (en) 2012-06-13 2014-08-05 Elwha Llc Breast implant with regionalized analyte sensors and internal power source
US8808373B2 (en) 2012-06-13 2014-08-19 Elwha Llc Breast implant with regionalized analyte sensors responsive to external power source
US9144489B2 (en) 2012-06-13 2015-09-29 Elwha Llc Breast implant with covering, analyte sensors and internal power source
US9803197B2 (en) 2012-06-25 2017-10-31 Emory University Particle-nucleic acid conjugates and therapeutic uses related thereto
CA2878945A1 (en) 2012-07-13 2014-01-16 Wave Life Sciences Pte. Ltd. Chiral control
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JP2015529809A (ja) 2012-07-27 2015-10-08 オームクス コーポレイション 酵素及び他の標的分析物の存在及び活性の切断前検出後の単分子層の電気測定
US9404883B2 (en) 2012-07-27 2016-08-02 Ohmx Corporation Electronic measurements of monolayers following homogeneous reactions of their components
CA2880678A1 (en) 2012-07-31 2014-02-06 Juan Carlos Jaime A procedure for obtaining and detecting a genetic marker of objects to be identified, the marker, method for authentication and method for verification
KR20150085806A (ko) * 2012-08-02 2015-07-24 디킨 유니버시티 암 줄기세포 검출을 위한 cd133 앱타머
CA2880833A1 (en) 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
ES2912033T3 (es) 2012-10-23 2022-05-24 Caris Science Inc Aptámeros y usos de los mismos
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
EP2912432B1 (de) 2012-10-24 2018-07-04 Genmark Diagnostics Inc. Integrierte multiplex-zielanalyse
PT2900277T (pt) 2012-12-13 2022-05-25 Immunomedics Inc Doses de imunoconjugados de anticorpos e sn-38 para melhorar a eficácia e diminuir a toxicidade
US9939443B2 (en) 2012-12-19 2018-04-10 Caris Life Sciences Switzerland Holdings Gmbh Compositions and methods for aptamer screening
FR3000105B1 (fr) * 2012-12-24 2015-05-15 Lvmh Rech Aptameres inhibiteurs de l'activite enzymatique de la tyrosinase
US9731032B2 (en) 2013-02-04 2017-08-15 The Cleveland Clinic Foundation Aptamers for tumor initiating cells
WO2014126213A1 (ja) 2013-02-15 2014-08-21 Ｎｅｃソリューションイノベータ株式会社 類似判断の候補配列情報の選択装置、選択方法、およびそれらの用途
EP2774930A1 (de) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocenverbindungen und markierte Moleküle damit für In-vivo-Bildgebung
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
US9052314B2 (en) 2013-03-14 2015-06-09 Silver Lake Research Corporation Biomarkers for detecting the presence of bacteria
EP2972386B1 (de) 2013-03-15 2018-01-10 Somalogic, Inc. Biomarker für nichtalkoholische fettlebererkrankung und nichtalkoholische steatohepatitis und verwendungen davon
WO2014143637A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
DK2970915T3 (da) 2013-03-15 2019-11-11 Maxcyte Inc Fremgangsmåder og sammensætninger til generering af stabile transficerede celler
US9850492B2 (en) 2013-03-22 2017-12-26 The University Of Tokyo Aptamer to IL-17 and use thereof
SG11201507967WA (en) 2013-03-27 2015-10-29 Theranos Inc Methods, devices, and systems for sample analysis
CN105283899A (zh) 2013-05-23 2016-01-27 艾弗诺泰普有限责任公司 用于保持或改善健康的方法和系统
GB201310203D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
WO2014197965A1 (en) 2013-06-12 2014-12-18 The Governing Council Of The University Of Toronto Catalytic nucleic acid and gold nanoparticles for detection of biomolecules
CA2915033C (en) 2013-06-12 2023-08-29 The General Hospital Corporation Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
CN105308073B (zh) 2013-06-14 2019-08-13 加利福尼亚太平洋生物科学股份有限公司 双生物素化标签
EP3014264A4 (de) 2013-06-25 2016-11-16 Two Pore Guys Inc Quantifizierung multiplexierter biomarker durch nanoporenanalyse von biomarker-polymer-komplexen
AU2014302038B2 (en) 2013-06-25 2019-11-14 Epiaxis Therapeutics Pty Ltd Methods and compositions for modulating cancer stem cells
WO2015006734A1 (en) 2013-07-12 2015-01-15 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
BR112016000853A2 (pt) 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
EP3757226A3 (de) 2013-07-17 2021-05-05 The Johns Hopkins University Multiprotein-biomarkertest für den nachweis von hirnläsionen und ergebnis
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
GB201314485D0 (en) 2013-08-13 2013-09-25 Electrophoretics Ltd Materials and methods relating to pancreatic cancer
EP2837939A1 (de) 2013-08-13 2015-02-18 Technische Universität München Verfahren zum Nachweis von H.pylori-Infektionen
BR102013021701A2 (pt) 2013-08-26 2015-07-28 Univ São Paulo Usp Polinucleotídeos quimicamente modificados e processo de produção de polinucleotídeos quimicamente modificados
JP2016533752A (ja) 2013-08-28 2016-11-04 カリス ライフ サイエンシズ スウィッツァーランド ホー オリゴヌクレオチドプローブおよびその使用
GB201315743D0 (en) 2013-09-04 2013-10-16 Maersk Olie & Gas Provision and uses of wettability modifiers
US11545241B1 (en) 2013-09-07 2023-01-03 Labrador Diagnostics Llc Systems and methods for analyte testing and data management
EP3693472A1 (de) 2013-09-09 2020-08-12 Somalogic, Inc. Pdgf- und vegf-aptamere mit erhöhter stabilität und deren verwendung bei der behandlung pdgf- und vegf-vermittelter krankheiten und leiden
US10016424B2 (en) 2013-09-16 2018-07-10 INSERM (Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of epilepsy
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
CA2926418A1 (en) 2013-10-08 2015-04-16 Promedior, Inc. Methods for treating fibrotic cancers
JP2017502075A (ja) 2013-11-04 2017-01-19 ノクソン ファーマ エージー 腎障害治療の手段および方法
GB201320061D0 (en) 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
EP3068882A2 (de) 2013-11-13 2016-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Kits von teilen mit nukleinsäuren mit fähigkeit zur bildung eines kissing-komplexes und verwendungen davon
AR093574A1 (es) 2013-11-21 2015-06-10 Consejo Nac De Investig Cientificas Y Tecn (Conicet) Aptameros contra la proteina basica de mielina como agentes neuroprotectores
EP3071588A4 (de) 2013-11-21 2017-08-02 Somalogic, Inc. Cytidin-5-carboxamid-modifizierte nukleotidzusammensetzungen und zugehörige verfahren
DE102013112915A1 (de) 2013-11-22 2015-05-28 Universitätsklinikum Hamburg-Eppendorf (UKE) DNA-Aptamere, die E- und P-Selektine spezifisch binden
KR20160095003A (ko) 2013-12-05 2016-08-10 사일런스 테라퓨틱스 게엠베하 폐 특이적 전달을 위한 수단
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
AU2014364593A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
CN105899537A (zh) 2014-01-10 2016-08-24 博笛生物科技（北京）有限公司 靶向表达egfr的肿瘤的化合物和组合物
EP3102708B1 (de) 2014-02-05 2020-11-18 Deakin University Aptamerkonstrukt
US10619210B2 (en) 2014-02-07 2020-04-14 The Johns Hopkins University Predicting response to epigenetic drug therapy
CA3152415A1 (en) 2014-02-18 2015-08-27 Somalogic Operating Co., Inc. Compositions and methods for detecting microorganisms
EP3590529A1 (de) 2014-03-12 2020-01-08 CureVac AG Kombination von impfstoffen und ox40-agonisten
CN106456542A (zh) 2014-03-17 2017-02-22 葛兰素史密斯克莱知识产权发展有限公司 用于局部递送的适体
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
JP6634554B2 (ja) 2014-03-24 2020-01-22 株式会社リボミック Ｆｇｆ２に対するアプタマー及びその使用
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
CA2962197C (en) 2014-04-18 2023-10-03 Ravindra Kumar Methods for increasing red blood cell levels and treating sickle-cell disease
WO2015164616A1 (en) 2014-04-24 2015-10-29 Somalogic, Inc. Biomarkers for detection of tuberculosis
WO2015164617A1 (en) 2014-04-24 2015-10-29 Somalogic, Inc. Tuberculosis biomarkers in urine and uses thereof
US9880121B2 (en) 2014-04-29 2018-01-30 Ohmx Corporation Bioelectronic binding assay using peak profiling
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
JP6673896B2 (ja) 2014-07-15 2020-03-25 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｍｅｋ阻害剤を使用した癌を処置するための組成物
US20160041118A1 (en) 2014-08-11 2016-02-11 Ohmx Corporation Enzyme triggered redox altering chemical elimination (e-trace) assay with multiplexing capabilities
EP3182917A1 (de) 2014-08-20 2017-06-28 Memorial Sloan Kettering Cancer Center Raman-ausgelöste ablation-/resektionssysteme und verfahren
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
CN107106517A (zh) 2014-08-25 2017-08-29 堪培拉大学 用于调节癌干细胞的组合物及其用途
JP2017526367A (ja) 2014-08-29 2017-09-14 チルドレンズ メディカル センター コーポレーション 癌の処置のための方法および組成物
EP3191843A1 (de) 2014-09-12 2017-07-19 Mediomics, LLC Molekulare biosensoren mit einem modularen design
WO2016044697A1 (en) 2014-09-19 2016-03-24 The Johns Hopkins University Biomarkers of cognitive dysfunction
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
EP3000483A1 (de) 2014-09-29 2016-03-30 Charité - Universitätsmedizin Berlin Mittel und Verfahren zur Diagnose und Behandlung von neurodegenerativen Erkrankungen
DE102014114834A1 (de) 2014-10-13 2016-04-14 Centrum Für Angewandte Nanotechnologie (Can) Gmbh Nanopartikel enthaltende Polymermizellen in nicht-wässriger Lösung, Methoden zu ihrer Herstellung und ihrer Anwendung
US11124822B2 (en) 2014-10-17 2021-09-21 Carnegie Mellon University Enhanced biomolecule detection assays based on tyramide signal amplification and gammaPNA probes
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
JP2017534633A (ja) 2014-11-06 2017-11-24 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｔｉｇｉｔ阻害剤を含む組み合わせ療法
WO2016075314A1 (fr) 2014-11-13 2016-05-19 Institut National De La Recherche Agronomique Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines
FR3028527A1 (fr) 2014-11-13 2016-05-20 Pivert Identification de facteurs de transcription de yarrowia lipolytica
CN107429075B (zh) 2014-11-17 2022-11-01 卡内基梅隆大学 可激活的双组份光敏剂
JP6768651B2 (ja) 2014-11-24 2020-10-14 ソマロジック, インコーポレイテッドSomaLogic, Inc. 増殖分化因子１１と結合するための核酸化合物
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
AU2015371265B2 (en) 2014-12-24 2021-06-03 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
WO2016123058A1 (en) 2015-01-27 2016-08-04 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
ES2873400T3 (es) 2015-02-02 2021-11-03 Meiragtx Uk Ii Ltd Regulación de la expresión génica a través de la modulación mediada por un aptámero del corte y empalme alternativo
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
TWI708845B (zh) 2015-02-09 2020-11-01 美商身體邏輯股份有限公司 用於結合生長分化因數8之核酸化合物
WO2016134365A1 (en) 2015-02-20 2016-08-25 The Johns Hopkins University Biomarkers of myocardial injury
WO2016135300A1 (en) 2015-02-26 2016-09-01 Qiagen Gmbh Efficiency improving methods for gene library generation
US10620185B2 (en) 2015-02-27 2020-04-14 Aptascan, Inc. Molecular barcoded bi-stable switch
WO2016138231A2 (en) 2015-02-27 2016-09-01 Sauder Timothy Lee Molcular barcoded bi-stable switch
EP3262185B1 (de) 2015-02-27 2020-08-26 The University of Hong Kong Dna-anzeige und verfahren dafür
WO2016145128A1 (en) 2015-03-09 2016-09-15 Caris Science, Inc. Oligonucleotide probes and uses thereof
WO2016145362A2 (en) 2015-03-12 2016-09-15 The Regents Of The University Of Michigan Inhibitors of dek protein and related methods
US9968523B2 (en) 2015-03-30 2018-05-15 Elwha Llc Systems and devices for controlling delivery of breast milk supplementation
US9925122B2 (en) 2015-03-30 2018-03-27 Elwha Llc Systems and methods for controlling delivery of breast milk supplementation
US10016341B2 (en) 2015-03-30 2018-07-10 Elwha Llc Systems and devices for controlling delivery of breast milk supplementation
US10160973B2 (en) 2015-03-30 2018-12-25 Nissan Chemical Industries, Ltd. Nucleic acid aptamers binding to vascular endothelial growth factor receptors
US10290372B2 (en) 2015-03-30 2019-05-14 Elwha Llc Systems and devices for controlling delivery of breast milk supplementation
AU2016243036B2 (en) 2015-04-03 2022-02-17 Abbott Laboratories Devices and methods for sample analysis
CA2981512A1 (en) 2015-04-03 2016-10-06 Abbott Laboratories Devices and methods for sample analysis
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN114736307A (zh) 2015-04-06 2022-07-12 阿塞勒隆制药公司 TGF-β超家族I型和II型受体异多聚体及其用途
JP6885876B2 (ja) 2015-04-13 2021-06-16 マックスサイト インコーポレーティッド ゲノムｄｎａを改変するための方法および組成物
EP3295176A1 (de) 2015-05-08 2018-03-21 Somalogic, Inc. Biomarker zur detektion des tuberkuloserisikos
CA2985818A1 (en) 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy
CA3026154A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
WO2016196945A1 (en) 2015-06-05 2016-12-08 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
CA2991045A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides binding c1q
WO2017004463A1 (en) 2015-07-01 2017-01-05 Abbott Laboratories Devices and methods for sample analysis
US11466093B2 (en) 2015-07-27 2022-10-11 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
WO2017019918A1 (en) 2015-07-28 2017-02-02 Caris Science, Inc. Targeted oligonucleotides
WO2017024182A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
AU2016301380B2 (en) 2015-08-04 2021-07-01 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
WO2017176265A1 (en) 2016-04-06 2017-10-12 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
DK3344805T3 (da) 2015-09-04 2022-03-07 Neoventures Biotechnology Inc Fremgangsmåde til udvælgelse af aptamerer til ubundne mål
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
JP2018532992A (ja) 2015-09-09 2018-11-08 ソマロジック, インコーポレイテッドSomaLogic, Inc. 個別化薬物治療計画の開発方法、及びプロテオミックプロファイルに基づく標的薬物開発
CA3003969A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
BR112018010052A2 (pt) 2015-11-19 2019-02-05 Asclepix Therapeutics Llc peptídeos com propriedades antiangiogênicas, antilinfangiogênicas e antiedêmicas e formulações de nanopartícula
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
WO2017089593A1 (en) 2015-11-26 2017-06-01 Universite Paris Descartes Inhibitors for treating or preventing a pulmonary arterial hypertension in systemic sclerosis patients and method for diagnosing said disease
JPWO2017094733A1 (ja) 2015-11-30 2018-09-13 日産化学株式会社 分子標的医薬に結合するｄｎａアプタマー及びそれを用いる分子標的医薬の検出方法
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
DE102016100039A1 (de) 2016-01-04 2017-07-06 Universitätsklinikum Hamburg-Eppendorf (UKE) α6-Integrin bindendes DNA-Aptamer
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
CN108934169A (zh) 2016-01-20 2018-12-04 维特里萨医疗公司 用于抑制因子d的组合物和方法
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
EP3405783B1 (de) 2016-01-22 2022-03-09 Purdue Research Foundation Markierungssystem mit geladener masse
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
JP6991979B2 (ja) 2016-02-05 2022-03-04 オリオニス バイオサイエンシズ ビーブイ Ｃｄ８結合物質
BR112018014842A8 (pt) 2016-02-08 2022-10-18 Somalogic Inc Métodos para determinar se um indivíduo tem doença hepática gordurosa não alcoólica (nafld) inflamação lobular, fibrose e hepatócitos balonizados referência cruzada aos pedidos relacionados
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CN109715802A (zh) 2016-03-18 2019-05-03 卡里斯科学公司 寡核苷酸探针及其用途
WO2017180871A1 (en) 2016-04-13 2017-10-19 Purdue Research Foundation Systems and methods for isolating a target in an ion trap
CA3020857A1 (en) 2016-04-14 2017-10-19 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2017187426A1 (en) 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
US11268135B2 (en) 2016-05-10 2022-03-08 Pattern Bioscience, Inc. Compositions and methods for identifying, quantifying, and/or characterizing an analyte
EP3454887B1 (de) 2016-05-13 2021-01-20 Orionis Biosciences BV Zielgerichtete mutanten-interferon-beta und verwendungen davon
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
WO2017205686A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
US10829563B2 (en) 2016-06-16 2020-11-10 INSERM (Institute National de la Santé et de la Recherche Médicale) Method of screening a candidate compound for activity as an elastase 2A (ELA2A) inhibitor
EP3263706A1 (de) 2016-06-28 2018-01-03 Centre National De La Recherche Scientifique (Cnrs) Auf snat7 abzielende wirkstoffe zur behandlung von erkrankungen im zusammenhang mit der zellstoffwechselumprogrammierung
CA3029178C (en) 2016-06-30 2022-07-19 Biois Co.,Ltd Double-stranded nucleic acid signal probe and method for detecting target molecule using same
TWI770036B (zh) 2016-07-01 2022-07-11 美商私募蛋白質體操作有限公司 包含經修飾核苷之寡核苷酸
EP3264092A1 (de) 2016-07-01 2018-01-03 Centogene AG Verwendung von lyso-gb1 als krankheitsassoziiertes ziel
WO2018013936A1 (en) 2016-07-15 2018-01-18 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
US11041863B2 (en) 2016-07-21 2021-06-22 Retinal Solutions Llc Frizzled-4 mutation indicator of retinopathy and intrauterine growth restriction
AU2017302282A1 (en) 2016-07-27 2019-02-07 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
US20190256853A1 (en) 2016-07-28 2019-08-22 Laboratoire Francais Du Fractionnement Et Des Biot Echnologies Method for Obtaining Aptamers
US9927441B1 (en) 2016-07-29 2018-03-27 X Development Llc Combinatorial methods for aptamer based proteomics
PT3494229T (pt) 2016-08-03 2024-02-20 Meiragtx Uk Ii Ltd Triagem de alto rendimento à base de células para aptâmeros
EP3502232A4 (de) 2016-08-22 2020-04-01 Nissan Chemical Corporation Zellgerüstmaterial mit e-cadherin-bindendem nukleinsäureaptamer
WO2018045238A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
EP3509643A1 (de) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Paclitaxel-albumin-bindende wirkstoffzusammensetzungen und verfahren zur verwendung und herstellung davon
EP3518981A4 (de) 2016-10-03 2020-06-10 President and Fellows of Harvard College Abgabe von therapeutischen rnas über arrdc1-vermittelte mikrovesikel
EA201990868A1 (ru) 2016-10-04 2019-09-30 Асклепикс Терапьютикс, Инк. СОЕДИНЕНИЯ И СПОСОБЫ АКТИВАЦИИ СИГНАЛЬНОЙ СИСТЕМЫ Tie2
WO2018067878A1 (en) 2016-10-05 2018-04-12 Abbott Laboratories Devices and methods for sample analysis
CN116650622A (zh) 2016-10-05 2023-08-29 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
AU2017338914B2 (en) 2016-10-05 2023-07-13 Abbott Laboratories Devices and methods for sample analysis
JP2019531351A (ja) 2016-10-14 2019-10-31 シーエヌエス バイオサイエンシーズ，インコーポレイティド 脊髄損傷者における神経障害性疼痛の治療
JP2019535249A (ja) 2016-10-24 2019-12-12 バイオイズ カンパニー リミテッド ＴＮＦ−α結合アプタマー及びその治療的用途
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
EP3315125A1 (de) 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipidnanopartikelformulierung
EP3536803A4 (de) 2016-11-02 2020-07-15 Biois Co., Ltd. Verfahren zur quantitative clusteranalyse des zielproteins mithilfe von sequenzierung der nächsten generation und verwendung davon
EP3332812A1 (de) 2016-12-07 2018-06-13 Rheinische Friedrich-Wilhelms-Universität Bonn Nukleinsäurebasierte anordnung und verwendung der anordnung in der krebstherapie
WO2018115083A1 (en) 2016-12-21 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of gut diseases such as irritable bowel syndrome (ibs)
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
MX2019009972A (es) 2017-02-21 2020-01-15 Meiragtx Uk Ii Ltd Regulación de la expresión génica de señales de poliadenilación por accesibilidad mediada por aptámeros.
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US20210145828A1 (en) 2017-06-29 2021-05-20 Rutgers, The State University Of New Jersey Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
EP3428184A1 (de) 2017-07-09 2019-01-16 Universitätsklinikum Hamburg-Eppendorf Mittel zur behandlung von herz-kreislauf-erkrankung
EP3661536A4 (de) 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. Verfahren zur identifizierung und herstellung von pharmazeutischen wirkstoffen zur aktivierung eines tie2-rezeptors
US10676748B2 (en) 2017-08-09 2020-06-09 The Procter & Gamble Company Aptamers for consumer product compositions
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US10934549B2 (en) 2017-08-18 2021-03-02 University Of Iowa Research Foundation Nucleic acid aptamers
CN111655340A (zh) 2017-09-20 2020-09-11 国家医疗保健研究所 用于调节自噬的方法和药物组合物
NL2019739B1 (en) 2017-10-16 2019-04-23 Academisch Ziekenhuis Leiden Means and methods for treating muscle degeneration
CN111542607A (zh) 2017-11-09 2020-08-14 力博美科股份有限公司 针对adamts5的适配体及其应用
SG11202005076PA (en) 2017-11-30 2020-06-29 Ribomic Inc Anti-chymase aptamer and use for same
US20200332296A1 (en) 2017-12-28 2020-10-22 Nuclixbio Aptamer template and method for preparing aptamer by using same
EP3521828A1 (de) 2018-01-31 2019-08-07 Centogene AG Verfahren zur diagnose eines hereditären angioödems
EP3749295A4 (de) 2018-02-05 2022-04-27 Orionis Biosciences, Inc. Fibroblastenbindende wirkstoffe und verwendung davon
AU2019232768A1 (en) 2018-03-05 2020-09-03 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus and a CDK4/6 inhibitor
US10481155B2 (en) 2018-03-09 2019-11-19 Somalogic, Inc. Proteomic assay using quantum sensors
EP3765065A2 (de) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Von sekretogranin v abgeleitete, antigene peptide und verwendungen davon zur diagnose und behandlung von diabetes typ 1
WO2019175384A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3765064A1 (de) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Pcsk2-abgeleitete antigene peptide und verwendungen davon zur diagnose und behandlung von diabetes typ 1
US20210140977A1 (en) 2018-04-16 2021-05-13 University Of Cape Town A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
FR3081169B1 (fr) 2018-05-15 2020-06-19 Messenger Biopharma Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'
BR112020024715A2 (pt) 2018-06-04 2021-03-23 Avon Products. Inc. biomarcadores proteicos para identificar e tratar o envelhecimento da pele e afecções cutâneas
WO2020005326A1 (en) 2018-06-29 2020-01-02 The Procter & Gamble Company Aptamers for personal care applications
WO2020005325A1 (en) 2018-06-29 2020-01-02 The Procter & Gamble Company Aptamers for hair care applications
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
JP7379505B2 (ja) 2018-10-02 2023-11-14 ウェアオプティモ ピーティーワイ リミテッド 流体レベルの判定
CA3115996A1 (en) 2018-10-15 2020-04-23 Somalogic, Inc. Nucleic acid compounds for binding immunoglobulin g
WO2020079248A1 (en) 2018-10-19 2020-04-23 Neoneuro Early detection of precursor of alzheimer's disease
JP7332694B2 (ja) 2018-12-04 2023-08-23 エフ． ホフマン－ラ ロシュ アーゲー 細胞標的の空間指向性量子バーコード化
WO2020115223A1 (en) 2018-12-05 2020-06-11 Katholieke Universiteit Leuven S100a4 as a marker of treatment with spironolactone, pioglitazone and metformin
EP3897652A4 (de) 2018-12-20 2022-09-14 KSQ Therapeutics, Inc. Substituierte pyrazolopyrimidine und substituierte purine und ihre verwendung als inhibitoren der ubiquitin-specific-processing protease 1 (usp1)
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
US11883401B2 (en) 2019-01-08 2024-01-30 Duke University Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
EP3914621A1 (de) 2019-01-21 2021-12-01 Singapore Health Services Pte. Ltd. Behandlung von hepatotoxizität
WO2020168024A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
AU2020223293A1 (en) 2019-02-15 2021-08-19 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
CN113508297A (zh) 2019-03-22 2021-10-15 私募蛋白质体公司 降低复杂生物基质中样品间分析物的可变性
WO2020201520A1 (en) 2019-04-04 2020-10-08 Carmentix Pte. Ltd. Biomarker pairs of preterm birth
WO2020201521A1 (en) 2019-04-04 2020-10-08 Carmentix Pte. Ltd. Biomarker pairs of preterm birth
EP3946332A1 (de) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Protease-aktivierte rezeptor-2-inhibitoren zur behandlung einer sensorischen neuropathie, die durch eine marine neurotoxische vergiftung induziert wird
EP3956451A1 (de) 2019-04-16 2022-02-23 The Procter & Gamble Company Aptamere für geruchsunterdrückungsanwendungen
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
MX2021013356A (es) 2019-05-03 2022-03-11 Singapore Health Serv Pte Ltd Tratamiento y prevencion de enfermedades metabolicas.
SG11202111365QA (en) 2019-05-17 2021-11-29 Somalogic Inc Controlling intersample analyte variability in complex biological matrices
GB201908544D0 (en) 2019-06-14 2019-07-31 Nat Univ Singapore Treatment and prevention of disease mediated by wwp2
US11198908B2 (en) 2019-06-17 2021-12-14 Biorchestra Co., Ltd. Method for diagnosis of Alzheimer's disease using microRNA
KR102113078B1 (ko) 2019-07-05 2020-05-20 광주과학기술원 압타머의 선별 방법
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021019196A1 (en) 2019-07-31 2021-02-04 University Of Dundee Analyte biosensing
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20220276256A1 (en) 2019-08-07 2022-09-01 Abbott Laboratories Methods for detecting assay interferents and increasing dynamic range
WO2021026402A1 (en) 2019-08-07 2021-02-11 Abbott Laboratories Chemiluminescent compounds for multiplexing
KR20220057534A (ko) 2019-09-03 2022-05-09 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 심혈관 위험 사건 예측 및 이의 용도
KR20220079551A (ko) 2019-09-05 2022-06-13 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 종양 세포 붕괴성 아데노바이러스, cdk4/6 억제제 및 추가의 치료 활성제의 조합물에 의한 종양의 치료
US20220333113A1 (en) 2019-10-16 2022-10-20 Somalogic Operating Co., Inc. Nucleic Acid Compounds that Bind to Retinoic Acid-Inducible Gene I Protein
BR112022011803A2 (pt) 2019-12-20 2022-08-30 Curevac Ag Nanopartículas de lipídio para entrega de ácidos nucleicos
US20230048910A1 (en) 2020-01-10 2023-02-16 Somalogic Operating Co., Inc. Methods of Determining Impaired Glucose Tolerance
EP4103948A1 (de) 2020-02-10 2022-12-21 SomaLogic Operating Co., Inc. Biomarker für nicht-alkoholische steatohepatitis (nash) und deren verwendungen
WO2021178923A1 (en) 2020-03-06 2021-09-10 Drinksavvy, Inc. Devices and methods for detecting a target analyte of interest
US20230096625A1 (en) 2020-03-10 2023-03-30 Abbott Laboratories Method for droplet loading into nanowells
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
GB2594094A (en) 2020-04-17 2021-10-20 Pockit Diagnostics Ltd Method for diagnosing stroke caused by large vessel occlusion
US20230220399A1 (en) 2020-05-07 2023-07-13 Interoligo Corporation Novel nucleic acid ligand and method for identifying same
WO2021236977A1 (en) 2020-05-21 2021-11-25 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2021256530A1 (ja) 2020-06-17 2021-12-23 株式会社リボミック Ｉｌ－２１に対するアプタマーおよびその使用
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
EP4172337A1 (de) 2020-06-25 2023-05-03 The Procter & Gamble Company Aptamere für körperpflegeanwendungen
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
EP4200250A1 (de) 2020-08-18 2023-06-28 Regenacellx.SL Zusammensetzungen und verfahren zum nachweis von sars-cov-2-spike-protein
US20230338574A1 (en) 2020-09-02 2023-10-26 Mayo Foundation For Medical Education And Research Antibody-nanoparticle complexes and methods for making and using the same
US20230374492A1 (en) 2020-10-07 2023-11-23 Centre National De La Recherche Scientifique (Cnrs) Process for selection of aptamers, riboswitches and desoxyriboswitches
BR112023004855A2 (pt) 2020-10-20 2023-05-02 Somalogic Operating Co Inc Predição de risco de evento cardiovascular
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
IL302352A (en) 2020-10-30 2023-06-01 Ksq Therapeutics Inc Solid-state forms of converted pyrazolopyrimidines and their uses
CN112779320B (zh) * 2020-12-04 2023-07-14 深圳市易基因科技有限公司 多区域dna甲基化检测探针设计及其检测方法
AU2021400488A1 (en) 2020-12-14 2023-06-22 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
CN116635038A (zh) 2020-12-18 2023-08-22 塔古西库斯生物株式会社 具有可用于dna适体筛选的新型人工碱基的脱氧核糖核苷、脱氧核糖核苷酸、及核酸
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
EP4284513A1 (de) 2021-01-26 2023-12-06 Universite Brest Bretagne Occidentale Neuartige stim1-spleissvarianten und verwendungen davon
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
CA3214113A1 (en) 2021-04-13 2022-10-20 Cate FOWLER Modified nucleosides
EP4323524A1 (de) 2021-04-14 2024-02-21 SomaLogic Operating Co., Inc. Coronavirusproteine bindende nukleinsäureverbindungen
US11578320B2 (en) 2021-04-27 2023-02-14 Singular Genomics Systems, Inc. High density sequencing and multiplexed priming
CA3221353A1 (en) 2021-06-15 2022-12-22 Laura SAMPSON Renal insufficiency prediction and uses thereof
WO2023278502A1 (en) 2021-06-30 2023-01-05 Somalogic Operating Co., Inc. Renal health determination and uses thereof
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
KR20230022813A (ko) 2021-08-06 2023-02-16 인터올리고 주식회사 비천연 핵산 리간드 및 이의 용도, 및 이를 유효성분으로 포함하는 암의 치료를 위한 약학적 조성물
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery
WO2023039522A1 (en) 2021-09-10 2023-03-16 Guardian Therapeutics, Llc Fatty acid conjugates of nucleic acids
CA3233512A1 (en) 2021-10-06 2023-04-13 Alexander Muik Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
WO2023057534A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
CA3233138A1 (en) 2021-10-07 2023-04-13 Leigh Alexander Lung cancer prediction and uses thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023066881A1 (en) 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
EP4263835A1 (de) 2021-12-14 2023-10-25 The Procter & Gamble Company Aptamere für körperpflegeanwendungen
WO2023111196A1 (en) 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
WO2023141248A1 (en) 2022-01-21 2023-07-27 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023154452A1 (en) 2022-02-11 2023-08-17 Waypoint Bio, Inc. Cellular staining probes for analyte detection
WO2023183873A1 (en) 2022-03-24 2023-09-28 Mensura Health Inc. Aptamers and uses thereof
WO2023211770A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023211769A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023211771A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023211773A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023235858A1 (en) 2022-06-03 2023-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered cell-penetrating antiviral compound
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024015486A1 (en) 2022-07-14 2024-01-18 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2024015485A1 (en) 2022-07-14 2024-01-18 Somalogic Operating Co., Inc. Methods of assessing dementia risk
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024030432A1 (en) 2022-08-01 2024-02-08 Gensaic, Inc. Therapeutic phage-derived particles
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
WO2024064322A2 (en) 2022-09-23 2024-03-28 Somalogic Operating Co., Inc. Methods of assessing tobacco use status
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016575A1 (de) * 1980-04-30 1981-11-05 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur immunologischen bestimmung von enzymen, mittel zur durchfuehrung des verfahrens und seine verwandung
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB2183661B (en) * 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US4942122A (en) * 1987-02-24 1990-07-17 Research Education Institute, Inc. Aids prognosis test detecting the presence of antibodies inhibiting HIV reverse transcriptase
US4935363A (en) * 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
WO1989006694A1 (en) * 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5043272A (en) * 1989-04-27 1991-08-27 Life Technologies, Incorporated Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers
US5070010A (en) * 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
CA2078659A1 (en) * 1990-03-21 1991-09-22 David J. Ecker Reagents and methods for modulating gene expression through rna mimicry
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
AU8547691A (en) * 1990-09-21 1992-04-15 Fred Hutchinson Cancer Research Center Protein sequence-specific oligonucleotide sequences
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
CA2104698A1 (en) * 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
AU1456092A (en) * 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
AU726844B2 (en) * 1995-06-07 2000-11-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands that bind to and inhibit DNA polymerases
US5861246A (en) * 1996-01-24 1999-01-19 Yale University Multiple selection process for binding sites of DNA-binding proteins
US5859227A (en) * 1996-07-31 1999-01-12 Bearsden Bio, Inc. RNA sequences which interact with RNA-binding proteins

Also Published As

Publication number Publication date
CA2084987A1 (en) 1991-12-12
EP1695978A1 (de) 2006-08-30
US6933116B2 (en) 2005-08-23
NZ238492A (en) 1993-07-27
IL112141A (en) 1998-04-05
ATE160821T1 (de) 1997-12-15
EP1493825A2 (de) 2005-01-05
DK0786469T3 (da) 2006-07-10
EP0786469B1 (de) 2006-03-01
JP2007195560A (ja) 2007-08-09
US6110900A (en) 2000-08-29
EP0533838A1 (de) 1993-03-31
ES2259800T3 (es) 2006-10-16
EP1493825A3 (de) 2005-02-09
JP2007195559A (ja) 2007-08-09
DK0533838T3 (da) 1998-02-23
JP2763958B2 (ja) 1998-06-11
RU2198931C2 (ru) 2003-02-20
JP4276272B2 (ja) 2009-06-10
IE980162A1 (en) 2000-02-23
DE69133513D1 (de) 2006-04-27
CA2084987C (en) 2007-02-13
EP0533838B1 (de) 1997-12-03
ES2110444T3 (es) 1998-02-16
KR970002255B1 (ko) 1997-02-26
EP0786469A2 (de) 1997-07-30
US20030198989A1 (en) 2003-10-23
IL98456A0 (en) 1992-07-15
JPH05507413A (ja) 1993-10-28
IE911979A1 (en) 1991-12-18
JPH08252100A (ja) 1996-10-01
GR3025594T3 (en) 1998-03-31
DE69128350T2 (de) 1998-03-26
ATE318832T1 (de) 2006-03-15
US5843653A (en) 1998-12-01
US5475096A (en) 1995-12-12
EP0533838A4 (en) 1993-05-26
AU8206191A (en) 1992-01-07
US20030157487A1 (en) 2003-08-21
US5696249A (en) 1997-12-09
EP0786469A3 (de) 1997-08-06
IL98456A (en) 1997-03-18
DE69133513T2 (de) 2006-09-21
WO1991019813A1 (en) 1991-12-26
US5670637A (en) 1997-09-23
US6331398B1 (en) 2001-12-18
AU663053B2 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
DE69128350T2 (de) Nukleinsäureliganden
RU92016539A (ru) Способ идентификации лигандов, способ получения антитела, способ отбора нуклеиновой кислоты, способ получения смеси нуклеиновых кислот, смесь нуклеиновых кислот, антитело
ATE274520T1 (de) Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex
AT399720B (de) Gewinnung von amphiregulin durch gentechnische verfahren
DE3860768D1 (de) Verfahren zur herstellung von hochduktilem tantal-halbzeug.
DE3873094T2 (de) Verfahren zur aufbereitung von gas.
DE3860106D1 (de) Verfahren zur brikettierung von kohle.
DE3865000D1 (de) Verfahren zur produktion von alkylaminen.
DE3862647D1 (de) Verfahren zur durchmischung von schuettguetern.
DE3484405D1 (de) Verfahren zur epoxidierung von olefinisch ungesaettigten verbindungen.
DE3874510T2 (de) Verfahren zur stabilisierung von hydroisomeraten.
DE3672242D1 (de) Verfahren zur dimerisierung von ethylenisch ungesaettigten verbindungen.
DE3874667D1 (de) Verfahren zur reinigung von methacrylsaeure.
DE3871001D1 (de) Verfahren zur reinigung von phenol.
DE3863549D1 (de) Verfahren zur beseitigung von abfaellen durch verbrennen mit sauerstoff.
DE59105908D1 (de) Verfahren zur Herstellung von Bis(hydroxymethyl)phosphinaten.
DK0415557T3 (da) Separation af antimetalchelat-antistoffer
DE3677663D1 (de) Verfahren zur nitrierung von phenolverbindungen.
DE68909515T2 (de) Durch Antikörper und Liganden bewirkte Zielrichtung von Differentiationsinduktoren auf Tumorzellen.
DE3879351T2 (de) Verfahren zur herstellung von bis(4-amino-phenyl)hexafluoropropan.
DE3775849D1 (de) Verfahren zur produktion von eisen-ii-sulfid.
DE3882674T2 (de) Verfahren zur bindung von biologischen reagenzien an poroese traeger.
ATE31486T1 (de) Verfahren zur mehrstufigen mischkondensation von daempfen.
DE69009772D1 (de) Verfahren zur produktion von organischen fluorierten verbindungen.
ES201262U (es) Losa rectangular prefabricada para la construccion de tabiques verticales no portantes.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8310 Action for declaration of annulment
8327 Change in the person/name/address of the patent owner

Owner name: GILEAD SCIENCES, INC., (N.D.GES.D. STAATES DELAWAR

8313 Request for invalidation rejected/withdrawn